Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53422

language	eng
Author	Tobita, Hiroshi Sato Shuichi Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan Miyake Tatsuya Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan ISHIHARA, Shunji Department of Internal Medicine II, Shimane University Faculty of Medicine Kinoshita, Yoshikazu
Subject	nonalcoholic; steatohepatitis; type 2 diabetes mellitus; sodium-glucose; cotransporter 2-inhibitor; dapagliflozin; open-label
Journal Title	CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Volume	87
Start Page	13
End Page	19
ISSN	0011-393X
ISSN（Online）	1879-0313
Published Date	2017
DOI	10.1016/j.curtheres.2017.07.002
PubMed ID	28912902
Publisher	ELSEVIER SCIENCE INC
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	Dapagliflozin was developed by AstraZeneca, who provided funding for publication fees and development of the manuscript, but did not play any other role in the study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. HT and YK have received honoraria from AstraZeneca K.K. Funding to pay for editorial support and the Open Access publication charges for this article were provided by AstraZeneca K.K. and Ono Pharmaceutical Co, Ltd. The authors have indicated that they have no other conflicts of interest regarding the content of this article.